

## EXEMPT DETERMINATION

May 2, 2023

Carol Schmitt  
970-498-1819  
[cschmitt@rti.org](mailto:cschmitt@rti.org)

Dear Carol Schmitt:

On 5/2/2023, the IRB reviewed the following submission:

Type of Review:	Modification / Update
Title:	FDA CTP Consumer Perceptions of Cessation and Harm Messaging (CHaRM) Study 1
Investigator:	Carol Schmitt
IRB ID:	MOD00001784
Funding Source:	FDA Ctr Tobacco Products
Customer/Client Name:	FDA Ctr Tobacco Products
Project/Proposal Number:	0217597.021.001.001
Contract/Grant Number:	75F40120A00017
IND, IDE, or HDE:	None

The IRB determined that this study meets the criteria for exemption from IRB review under Category (2) (iii) Tests, surveys, interviews, or observation (identifiable); and for which limited IRB review was conducted via expedited review.

Ongoing IRB review and approval by this organization is not required. This determination applies only to the activities described in the IRB submission and may not apply should any changes be made. If changes are made and there are questions about whether these activities impact the exempt determination, you should contact the IRB to discuss whether a new submission and determination is necessary.

Sincerely,

The RTI Office of Research Protection